216 related articles for article (PubMed ID: 22425215)
1. TFPI-dependent activities of protein S.
Peraramelli S; Rosing J; Hackeng TM
Thromb Res; 2012 May; 129 Suppl 2():S23-6. PubMed ID: 22425215
[TBL] [Abstract][Full Text] [Related]
2. Protein S is a cofactor for tissue factor pathway inhibitor.
Rosing J; Maurissen LF; Tchaikovski SN; Tans G; Hackeng TM
Thromb Res; 2008; 122 Suppl 1():S60-3. PubMed ID: 18691502
[TBL] [Abstract][Full Text] [Related]
3. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
Hackeng TM; Seré KM; Tans G; Rosing J
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3106-11. PubMed ID: 16488980
[TBL] [Abstract][Full Text] [Related]
4. Protein S as cofactor for TFPI.
Hackeng TM; Rosing J
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2015-20. PubMed ID: 19661488
[TBL] [Abstract][Full Text] [Related]
5. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of LDL-associated tissue factor pathway inhibitor.
Augustsson C; Hilden I; Petersen LC
Thromb Res; 2014 Jul; 134(1):132-7. PubMed ID: 24787991
[TBL] [Abstract][Full Text] [Related]
7. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.
Santamaria S; Reglińska-Matveyev N; Gierula M; Camire RM; Crawley JTB; Lane DA; Ahnström J
J Biol Chem; 2017 Jun; 292(22):9335-9344. PubMed ID: 28420729
[TBL] [Abstract][Full Text] [Related]
8. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
[TBL] [Abstract][Full Text] [Related]
9. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants.
Liestøl S; Sandset PM; Jacobsen EM; Mowinckel MC; Wisløff F
Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306
[TBL] [Abstract][Full Text] [Related]
10. The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography.
Audu P; Nielsen VG; Armstead V; Powell G; Kim J; Kim L; Mehta M
Anesth Analg; 2006 Oct; 103(4):841-5. PubMed ID: 17000790
[TBL] [Abstract][Full Text] [Related]
11. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.
Ndonwi M; Tuley EA; Broze GJ
Blood; 2010 Aug; 116(8):1344-51. PubMed ID: 20479289
[TBL] [Abstract][Full Text] [Related]
12. Platelet tissue factor pathway inhibitor modulates intravascular coagulation.
Maroney SA; Mast AE
Thromb Res; 2012 May; 129 Suppl 2(Suppl 2):S21-2. PubMed ID: 22425319
[TBL] [Abstract][Full Text] [Related]
13. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Peraramelli S; Suylen DP; Rosing J; Hackeng TM
Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
[TBL] [Abstract][Full Text] [Related]
14. Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Meijers JC; Porte RJ; Lisman T
Br J Haematol; 2013 Sep; 162(6):819-26. PubMed ID: 23841464
[TBL] [Abstract][Full Text] [Related]
15. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa.
Evenäs P; García de Frutos P; Nicolaes GA; Dahlbäck B
Thromb Haemost; 2000 Aug; 84(2):271-7. PubMed ID: 10959700
[TBL] [Abstract][Full Text] [Related]
16. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Tchaikovski SN; Thomassen MC; Costa SD; Peeters LL; Rosing J
Thromb Haemost; 2011 Nov; 106(5):914-21. PubMed ID: 21979881
[TBL] [Abstract][Full Text] [Related]
17. C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa.
van de Poel RH; Meijers JC; Bouma BN
Thromb Haemost; 2001 May; 85(5):761-5. PubMed ID: 11372664
[TBL] [Abstract][Full Text] [Related]
18. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
[TBL] [Abstract][Full Text] [Related]
19. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution.
De Smedt E; Wagenvoord R; Coen Hemker H
Thromb Haemost; 2009 Jan; 101(1):165-70. PubMed ID: 19132204
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
